Charles Schwab’s Rallybio RLYB Stock Holding History

Charles Schwab’s Portfolio RLYB Stock Details RLYB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,627	Closed	-$142K	–	3671
2024 Q1	$142K	Hold	9,627	–	–	﹤0.01%	3274
2023 Q4	$184K	Hold	9,627	–	–	﹤0.01%	3283
2023 Q3	$260K	Hold	9,627	–	–	﹤0.01%	3241
2023 Q2	$436K	Buy	9,627 +2,795	+41%	+$137K	﹤0.01%	3117
2023 Q1	$312K	Buy	6,832 +1,022	+18%	+$52.8K	﹤0.01%	3081
2022 Q4	$305K	Buy	5,810 +779	+15%	+$46K	﹤0.01%	3106
2022 Q3	$583K	Hold	5,031	–	–	﹤0.01%	2958
2022 Q2	$304K	Sell	5,031 -667	-12%	-$50.1K	﹤0.01%	3189
2022 Q1	$319K	Buy	5,698 +3,688	+183%	+$305K	﹤0.01%	3205
2021 Q4	$154K	Buy	2,010 +204	+11%	+$23.7K	﹤0.01%	3397
2021 Q3	$254K	Buy	+1,806	New	+$212K	﹤0.01%	3296

Other funds holding RLYB

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CPX

Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab's RLYB Position: Q2 2024 in Review

Charles Schwab sold out of Rallybio (RLYB) in Q2 2024, closing a stake of 9,627 shares — an estimated $142K sold.

Charles Schwab first reported a position in RLYB in Q3 2021 and held it in 11 quarters. The position peaked at $583K in Q3 2022. 66 funds tracked by Wall St. Rank hold RLYB as of Q2 2024.

Charles Schwab reported no remaining Rallybio position as of Q2 2024 after selling out during the quarter.
Charles Schwab sold 9,627 Rallybio shares in Q2 2024, an estimated $142K.
Charles Schwab first reported a position in Rallybio in Q3 2021 and held it in 11 quarters.
Charles Schwab's Rallybio position peaked at $583K in Q3 2022.
66 funds tracked by Wall St. Rank held Rallybio as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.